Research & Development

Aiming to be the Global Pharma Innovator with Competitive Advantage in Oncology, Daiichi Sankyo will focus our research and development resources on certain disease areas through prioritization, such as oncology and cardiovascular-metabolics. The decision making would be driven by diversified viewpoints based on science and business perspectives from our supreme decision-making body – GEMRAD (Global Executive Meeting of Research and Development), to maximize research outcomes.

Daiichi Sankyo established an R&D system at three pivotal sites (Japan, the U.S. and Europe), where we collaborate closely in all the stages from drug discovery to development and manufacture. Furthermore, we have established R&D locations in key emerging markets, Shanghai and Beijing in China. We expect that the roles of these emerging markets would become more important in the future.

Worldwide R&D Organization

If you want to know more about Daiichi Sankyo's R&D information, please click here.

Who We Are

Daiichi Sankyo is a global pharmaceutical company striving to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals.
read more ...

体彩p3走势图连线 国际尊宝娱乐 浙江体彩历史开奖查询飞鱼 体彩浙江6+1走势图 十一选五内蒙古 内蒙古快三早知道推荐 股票配资网找象泰配资负责GO 股票投资要义 三一重工股票行情 湖南快乐十分玩法 云南快乐十分遗漏